Heiner Wedemeyer Selected Research

peginterferon alfa-2a (Pegasys)

1/2020	Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a.
1/2020	Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B.
1/2019	Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.
1/2019	Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data.
1/2018	No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B.
1/2016	Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.
10/2015	Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders.
1/2015	Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy.
1/2015	Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study.
1/2011	Peginterferon plus adefovir versus either drug alone for hepatitis delta.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Heiner Wedemeyer Research Topics

Disease

169	Infections 11/2022 - 02/2002
63	Chronic Hepatitis C 06/2022 - 02/2002
63	Hepatitis C 01/2022 - 07/2004
58	Fibrosis (Cirrhosis) 12/2022 - 11/2004
34	Chronic Hepatitis B 11/2022 - 10/2007
30	Liver Diseases (Liver Disease) 01/2022 - 01/2007
30	Hepatocellular Carcinoma (Hepatoma) 07/2021 - 12/2004
27	Hepatitis B 11/2022 - 01/2003
25	Hepatitis D 01/2022 - 03/2009
22	Liver Cirrhosis (Hepatic Cirrhosis) 04/2022 - 11/2004
22	Hepatitis 02/2022 - 01/2005
18	Chronic Hepatitis (Chronic Active Hepatitis) 11/2022 - 01/2010
17	Neoplasms (Cancer) 05/2022 - 03/2005
15	Virus Diseases (Viral Diseases) 01/2021 - 02/2002
10	Disease Progression 01/2022 - 10/2008
10	Viremia 10/2020 - 01/2008
9	Inflammation (Inflammations) 12/2022 - 01/2010
9	Coinfection 07/2021 - 03/2007
8	Ascites 04/2022 - 01/2017
8	Autoimmune Hepatitis 01/2022 - 01/2011
7	Hepatitis E 01/2022 - 01/2011
7	Non-alcoholic Fatty Liver Disease 01/2021 - 12/2016
7	Liver Failure 01/2021 - 11/2007
6	End Stage Liver Disease 12/2020 - 03/2008
5	Hemorrhage 01/2022 - 09/2014
5	Persistent Infection 01/2022 - 02/2006
5	HIV Infections (HIV Infection) 01/2020 - 10/2011
4	Portal Hypertension 04/2022 - 11/2015
4	Communicable Diseases (Infectious Diseases) 01/2021 - 12/2012
4	Reinfection 11/2019 - 10/2006
4	Hepatitis A (Hepatitis, Infectious) 11/2018 - 12/2006
4	Chronic Hepatitis D 01/2016 - 03/2010
3	Wounds and Injuries (Trauma) 12/2022 - 09/2018
3	Thrombocytopenia (Thrombopenia) 01/2022 - 09/2014
3	Sclerosing Cholangitis 06/2021 - 01/2011
3	Liver Neoplasms (Liver Cancer) 01/2021 - 01/2017
3	Diabetes Mellitus 07/2019 - 06/2008

Drug/Important Bio-Agent (IBA)

84	Antiviral Agents (Antivirals)IBA 06/2022 - 11/2004
61	InterferonsIBA 01/2022 - 02/2002
52	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2005
51	Ribavirin (Virazole)FDA LinkGeneric 01/2022 - 02/2002
33	Hepatitis B Surface Antigens (HBsAg)FDA Link 11/2022 - 01/2008
24	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 10/2007
21	Interferon-alpha (Interferon Alfa)IBA 01/2022 - 02/2002
17	AntigensIBA 11/2022 - 10/2007
17	VaccinesIBA 05/2022 - 10/2006
16	Biomarkers (Surrogate Marker)IBA 11/2022 - 11/2011
14	Proteins (Proteins, Gene)FDA Link 01/2022 - 07/2004
13	Hepatitis B e AntigensIBA 11/2022 - 01/2008
13	CytokinesIBA 01/2022 - 10/2011
13	AntibodiesIBA 01/2022 - 01/2009
13	Pharmaceutical PreparationsIBA 03/2021 - 05/2008
11	Peptides (Polypeptides)IBA 10/2019 - 09/2007
10	peginterferon alfa-2a (Pegasys)FDA Link 01/2020 - 01/2011
9	BilirubinIBA 12/2021 - 03/2008
9	Protease Inhibitors (Protease Inhibitor)IBA 01/2021 - 04/2005
8	AlbuminsIBA 12/2021 - 08/2014
8	telaprevirIBA 01/2016 - 01/2013
7	Alanine Transaminase (SGPT)IBA 01/2022 - 01/2008
7	glecaprevir and pibrentasvirIBA 01/2022 - 01/2018
7	SofosbuvirIBA 01/2020 - 01/2014
7	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 01/2016 - 02/2009
6	Surface Antigens (Surface Antigen)IBA 01/2018 - 01/2008
6	entecavir FDA Link 11/2016 - 04/2010
6	adefovirIBA 12/2015 - 01/2011
5	EnzymesIBA 12/2022 - 09/2014
5	Immunoglobulins (Immunoglobulin)IBA 12/2021 - 10/2006
5	Ritonavir (Norvir)FDA Link 11/2018 - 05/2014
5	dasabuvirIBA 11/2018 - 05/2014
5	ombitasvirIBA 11/2018 - 05/2014
5	paritaprevirIBA 11/2018 - 05/2014
4	Aspartate Aminotransferases (Aspartate Transaminase)IBA 12/2021 - 01/2020
4	EpitopesIBA 10/2019 - 12/2009
4	Tenofovir (Viread)FDA Link 01/2019 - 01/2010
4	Viral RNAIBA 01/2018 - 11/2004
4	NucleosidesIBA 06/2013 - 10/2006
3	Norepinephrine (Noradrenaline)FDA LinkGeneric 12/2022 - 11/2021
3	bulevirtideIBA 11/2022 - 01/2019
3	Immunoglobulin G (IgG)IBA 01/2022 - 01/2010
3	sofosbuvir drug combination ledipasvirIBA 01/2022 - 10/2016
3	Interleukin-17 (Interleukin 17)IBA 01/2021 - 10/2019
3	LigandsIBA 01/2021 - 05/2010
3	InterleukinsIBA 01/2021 - 10/2011
3	Messenger RNA (mRNA)IBA 01/2020 - 05/2010
3	Transaminases (Aminotransferases)IBA 01/2020 - 09/2018
3	daclatasvirIBA 01/2018 - 02/2015
3	Interferon Type IIBA 01/2015 - 07/2009
3	Hepatitis delta Antigens (HDAg)IBA 09/2014 - 01/2011

Therapy/Procedure

124	Therapeutics 12/2022 - 12/2002
36	Liver Transplantation 12/2022 - 10/2006
8	Duration of Therapy 01/2020 - 10/2006
7	Transplantation 01/2021 - 01/2010
6	Immunotherapy 01/2020 - 03/2005
5	Drug Therapy (Chemotherapy) 01/2018 - 10/2010
4	Transjugular Intrahepatic Portasystemic Shunt 04/2022 - 01/2018
4	Surgical Portasystemic Shunt (Portosystemic Shunt) 04/2022 - 05/2017
4	Aftercare (After-Treatment) 01/2021 - 12/2015
4	Opiate Substitution Treatment 01/2019 - 07/2013
3	Contraindications 01/2022 - 05/2017
3	Drug Tapering 06/2015 - 11/2013